NORTH CHICAGO, Ill. and
LA JOLLA, Calif., Dec. 9, 2019 /PRNewswire/ -- AbbVie (NYSE:
ABBV), a research-based global biopharmaceutical company and
Scripps Research, an international leader in non-profit biomedical
research and drug discovery, today announced a collaboration to
develop new therapies for a range of diseases, including in the
therapeutic areas of oncology, immunology, neurology and
fibrosis.
"Based on our strong switchable CAR-T alliance launched in 2018,
we feel the expanded relationship with AbbVie represents a robust
path forward for some of our programs, complementing a diverse
ecosystem of innovation we've created over the past several years
at Scripps to advance life-changing therapies," says Peter Schultz, Ph.D., chief executive officer,
Scripps Research and Calibr, its drug discovery division.
In addition to programs initially named in the collaboration
from preclinical to IND stages of development, Scripps Research
will present to AbbVie a certain number of preclinical programs of
mutual interest per year for consideration to be included in the
collaboration. Scripps and AbbVie will also work together in
parallel to advance CD3 bispecifics against oncology targets
nominated by AbbVie.
Under the terms of the license agreement, Scripps Research will
continue to conduct pre-clinical research and development
activities and, in some cases, Phase 1 clinical trials with AbbVie
having an exclusive option to further develop and
commercialize.
Upon AbbVie's decision to exercise its option to a given
program, Scripps Research is eligible to receive additional
payments from AbbVie, including option exercise fees, success-based
development and commercial milestone payments, as well as tiered
royalties. AbbVie will make an undisclosed upfront payment, as well
as a near-term milestone payment upon achievement of certain
success criteria.
"The best way to develop transformational medicines is through
collaborations that bring together the brightest minds," says
Mohit Trikha, Ph.D., vice president
and head of oncology early development, AbbVie. "This partnership
with Scripps Research will collaboratively advance next generation
programs, build stronger relationships with proven and emerging
scientific leaders, and most importantly help us advance novel
medicines for patients. We are eager to partner with Scripps on
these assets as they enter the clinic over the next few years as
Scripps has one of the strongest track records of any academic
institution when it comes to advancing novel medicines for
patients."
About AbbVie
AbbVie is a global, research and development-based
biopharmaceutical company committed to developing innovative
advanced therapies for some of the world's most complex and
critical conditions. The company's mission is to use its expertise,
dedicated people and unique approach to innovation to markedly
improve treatments across four primary therapeutic areas:
immunology, oncology, virology and neuroscience. In more than
75 countries, AbbVie employees are working every day to advance
health solutions for people around the world. For more information
about AbbVie, please visit us at www.abbvie.com.
Follow @abbvie on Twitter, Facebook, LinkedIn or
Instagram.
About Scripps Research
Scripps Research, with campuses in California and Florida, ranks as the most influential
scientific organization in the world, unparalleled in propelling
innovation in science and medicine. Our unique structure merges
foundational studies in biology, chemistry and computer science
with translational science to produce the next generation of drugs
and advances in digital and precision medicine. Scientists in the
institute's five academic research departments work hand-in-hand
with researchers of the Scripps Research Translational Institute
and Calibr. Together, we cultivate the next generation of
scientific leaders and expand the frontiers of knowledge to drive
innovation that improves lives around the planet.
For more information about Calibr and Scripps Research visit
www.calibr.org and www.scripps.edu. Follow
@ScrippsResearch on Twitter, Facebook or LinkedIn.
View original
content:http://www.prnewswire.com/news-releases/abbvie-and-scripps-research-announce-collaboration-to-develop-a-broad-range-of-new-therapeutics-300971084.html
SOURCE AbbVie